[HTML][HTML] Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF …

…, PA Ott, GV Long, OS Gardner… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Purpose BRAF mutations promote melanoma cell proliferation and survival primarily through
activation of MEK. The purpose of this study was to determine the response rate (RR) for …

Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling

OS Gardner, BJ Dewar, LM Graves - Molecular pharmacology, 2005 - ASPET
… (OS Gardner, unpublished observations). Other mechanisms, such as the possible role of
Pyk2 and changes in intracellular calcium concentration, remain undetermined. Furthermore, …

[HTML][HTML] Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor …

OS Gardner, BJ Dewar, HS Earp, JM Samet… - Journal of Biological …, 2003 - ASBMB
Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that
function as ligand-activated transcription factors regulating lipid metabolism and homeostasis. …

[HTML][HTML] A phase 1/1b study evaluating trametinib plus docetaxel or pemetrexed in patients with advanced non–small cell lung cancer

…, FA Shepherd, J Mazieres, F Janku, OS Gardner… - Journal of thoracic …, 2017 - Elsevier
Objectives This two-part study evaluated trametinib, a MEK1/2 inhibitor, in combination with
anticancer agents. Inhibition of MEK, a downstream effector of KRAS, demonstrated …

[HTML][HTML] Peroxisome proliferator-activated receptor γ-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein …

OS Gardner, CW Shiau, CS Chen, LM Graves - Journal of Biological …, 2005 - ASBMB
The thiazolidinediones (TZDs) are synthetic peroxisome proliferator-activated receptor γ (PPARγ)
ligands that promote increased insulin sensitivity in type II diabetic patients. In addition …

A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma

…, KM Koch, JW Bauman, OS Gardner… - Journal of …, 2013 - journals.lww.com
Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical
models. Rituximab is a CD20 monoclonal antibody with activity against human B-cell …

[HTML][HTML] Auto-inhibition of the Dbl family protein Tim by an N-terminal helical motif

ME Yohe, KL Rossman, OS Gardner… - Journal of biological …, 2007 - ASBMB
Dbl-related oncoproteins are guanine nucleotide exchange factors specific for Rho-family
GTPases and typically possess tandem Dbl homology (DH) and pleckstrin homology domains …

Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC …

…, Y Wu, DJ Schramek, AM Piepszak, OS Gardner… - 2013 - ascopubs.org
8028 Background: KRAS-mutant NSCLC, usually reflecting tobacco-related carcinogenesis,
represents an unmet medical need in lung cancer therapy. Trametinib plus docetaxel (doc) …

Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer …

…, Y Wu, DJ Schramek, DS Cox, OS Gardner… - 2013 - ascopubs.org
8027 Background: Lung cancer patients with mutated KRAS tumors present a treatment
challenge. Trametinib + pemetrexed (pem) enhanced growth inhibition and apoptosis compared …

Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones

BJ Dewar, OS Gardner, CS Chen, HS Earp… - Molecular …, 2007 - ASPET
Thiazolidinediones (TZDs) are synthetic ligands for the peroxisome proliferator-activated
receptor γ (PPARγ) but also elicit PPARγ-independent effects, most notably activation of …